In Vivo Nuclear Molecular Imaging in Drug Development and Pharmacological Research

doi:10.3390/books978-3-0365-7390-8

Download Url(s)

https://mdpi.com/books/pdfview/book/7256

Contributor(s)

Yue, Xuyi (editor)

Language

English

Show full item record

Abstract

This Special Issue published one editorial, eight articles and four reviews from approximately one hundred authors. It aimed to provide cutting-edge research on pre-clinical development and the clinical translation of radiopharmaceuticals within the molecular imaging community. The Special Issue covered radioligand development, existing radiotracer optimization, imaging agent evaluation in animal models, the clinical production of radiopharmaceuticals, and investigative research on the use of molecular imaging probes in human subjects. We appreciate all the authors’ significant contributions to this Special Issue and hope the readers will enjoy the content.

URI

https://directory.doabooks.org/handle/20.500.12854/100794

Keywords

nanoparticle; multimodal imaging; photoacoustic; heterobivalent peptide; Alzheimer’s disease; amyloid-beta; animal model; astrocyte; blood–brain barrier; imaging; metabolism; microglia; neuroinflammation; neurotransmitter receptors; positron emission tomography; synaptic density; vascular imaging; FDG; PET/CT; microvasculature imaging; ABC-transporter; drug-induced liver injury; hepatotoxicity; organic anion-transporting polypeptide; pharmacokinetics; liver function; SLC-transporter; V/Q PET/CT; [68Ga]Ga-MAA; 68Ga-labelled carbon nanoparticles; glioblastoma; fluorescence guided surgery; 5-ALA; fluorescein; NIR-AZA; magnetic resonance imaging; high resolution; hybrid imaging; psychiatric disorders; extracellular vesicles (EVs); umbilical cord mesenchymal stem cell (UCMSC); diabetes; I-124; positron emission tomography (PET); intravenous (I.V.) administration; intra-arterial (I.A.) administration; biodistribution; fluorine-18; PET; oxime; PSMA; lipophilicity; radiometals; copper-61; liquid targets; post-processing; [61Cu]Cu-DOTA-NOC; [61Cu]Cu-DOTA-TOC; [61Cu]Cu-DOTA-TATE; FAP; 99mTc-FAP inhibitor; 99mTc-labeled iFAP; tumor microenvironment; SPECT; GluN1/2B receptors; NMDA; [3H]ifenprodil; σ1 and σ2 receptors; receptor occupancy; PET imaging; drug development; neurodegenerative diseases; n/a